| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Exicure, Inc.$1.6
+0.03 (+1.91%)
D 33Pipeline Score Overvalued Biotech · Clinical
Market Cap
17.91 M
EPS
-0.77
P/E Ratio
-
Value Trade
8.34 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
312.00 K
Operating CF
-1.14 M
Total Assets
12.76 M
Total Liabilities
10.66 M
Equity
2.10 M
D/E Ratio
12,345
-6.33 %
Week
-25.07 %
1 Month
-23.64 %
3 Month
-31.96 %
6 Month
-98.93 %
5 Year
-99.38 %
All Time
Cash Data
Cash Position
2.60 M
Monthly Burn
381.00 K
Runway
4.8 mo
Burn Trend
SEC Filing
May 29, 2026
Overview
Volume
17.70 K
52 Week Range
2.63 - 10.80
% held by Insiders
43.87 %
% held by Institutions
1.81 %
Enterprise Value
14.34 M
Total Shares
6.37 M
Short %
11.84 %
Float Shares
4.28 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Exicure, Inc.
269Total events
5Upcoming
61Tier-1 (high impact)
2016 – 2026Coverage
Upcoming catalysts 2
TBD
T3Preclinical PoC
Subscribe to view catalyst details
TBD
T3IND Enabling Complete
Subscribe to view catalyst details
Event history 2
TBD
◆Timing GuidancePresentation
Subscribe to view catalyst details
TBD
▼Restructuring LayoffsCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-02-05 | Burixafor (GPC-100) | phase 2 data readout | Phase 2 | — | – | – | – |
2026-02-05 | Burixafor (GPC-100) | phase 2 data readout | Phase 2 | — | – | – | – |
2026-02-05 | Burixafor (GPC-100) | phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D33
Pipeline Score $4M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.2x
rNPV / MCap Top 44%
Micro Cap (rank 512 of 913)
Percentile RankExicure, Inc. faces pipeline headwinds (33/100), with $2.7B risk-adjusted pipeline value, led by TG-0054 combined with G-CSF in Multiple Myeloma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TG-0054 combined with G-CSF Small molecule | Multiple Myeloma | Phase 2 | NCT02104427 | 19% | $876M | COMPLETED | 12 | - | - | Nov 1, 2015 | - | Apr 19, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
burixafor | multiple myeloma and lymphoma | Phase 2 | 2026-02-05 | 92%, 11 of 12 participants, 12 days, 22 days, 11-fold | Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant Read More | |
burixafor | multiple myeloma and lymphoma | Phase 2 | 2026-02-05 | 92%, 11 of 12 participants, 12 days, 22 days, 11-fold | Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant Read More | |
burixafor | multiple myeloma and lymphoma | Phase 2 | 2026-02-05 | 92%, 11 of 12 participants, 12 days, 22 days, 11-fold | Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XCUR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
XCUR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XCUR▼ -5.5%on this news
Exicure Announces Board and Committee Changes
Exicure, Inc. has announced changes to its Board of Directors, including the resignation of Jung Kyu Ham and the appointment of Jin Young Go and Eui Seok Han as new directors. The Board size has increased from five to six members, maintaining compliance with Nasdaq independence standards. Additionally, a new Compensation Committee has been established.
Read more →XCURExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Exicure, Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement. The company reported equity of approximately $2.1 million, below the $2.5 million threshold. Exicure plans to submit a compliance plan within 45 days and is exploring options to improve its financial standing. The notification does not immediately affect its stock listing.
Read more →XCUR▼ -6.6%on this news
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure, Inc. received a delinquency notice from Nasdaq due to a delay in filing its Quarterly Report on Form 10-Q for Q1 2026. The delay was attributed to changes in financial reporting personnel. However, the company has since filed the report and believes it has regained compliance with Nasdaq regulations. Exicure is also exploring strategic alternatives following a restructuring.
Read more →XCURExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Exicure, Inc. has entered a co-development agreement with Adbiotech to explore combination therapies using Burixafor (GPC-100) in several therapeutic areas, including sickle cell disease and acute myeloid leukemia. The collaboration will see Adbiotech conduct preclinical research while Exicure will lead clinical strategies. Notably, Burixafor has shown promise after completing a Phase 2 trial in multiple myeloma, laying a foundation for further studies. The agreement aims to advance clinical programs and secure funding for future development.
Read more →XCURExicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. reported its financial results for 2025, revealing a net loss of $4.9 million, an improvement from the previous year's loss of $9.7 million. The company faces liquidity challenges, with cash reserves insufficient to sustain operations for the next year. Increased expenses were noted due to the acquisition of GPCR Therapeutics USA Inc., necessitating additional financing to support ongoing operations and strategic alternatives.
Read more →XCURUNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION IN RE EXICURE, INC. DERIVATIVE LITIGATION This Document Relates to ALL ACTIONS Lead Case No. 1 22-cv-01083 EXHIBIT C NOTICE OF PENDENCY AND PROP
Exicure, Inc. is poised to settle a derivative litigation case involving allegations of fiduciary breaches by former directors. The settlement, proposed on March 18, 2026, includes the implementation of new corporate governance reforms aimed at benefiting the company and its stockholders. However, if approved, current stockholders will be barred from contesting the settlement and pursuing related claims in the future. The court is set to hold a hearing on June 2, 2026, to evaluate the fairness and adequacy of the proposed settlement.
Read more →XCURExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Exicure, Inc. announced the publication of a Phase 2 study in the Annals of Hematology, highlighting the efficacy of burixafor in rapidly mobilizing stem cells in patients with multiple myeloma and lymphoma undergoing transplant. The study showed that 92% of participants achieved the primary endpoint, with significant increases in white blood cell subsets. Burixafor's rapid mobilization profile may simplify treatment logistics and reduce patient burden.
Read more →XCURExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Exicure, Inc. will present data from its Phase 2 trial of burixafor at the 2026 Tandem Meetings. The trial evaluated burixafor's effectiveness in mobilizing hematopoietic progenitor cells for patients with multiple myeloma undergoing autologous transplantation. The study reported a high success rate in achieving the primary endpoint, highlighting burixafor's potential as a reliable mobilization strategy.
Read more →XCUR▲ +36.8%on this news
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Exicure, Inc. announced positive results from its Phase 2 trial of burixafor for multiple myeloma. Approximately 90% of participants achieved the primary endpoint for hematopoietic progenitor cell mobilization. The combination therapy was well tolerated, showing a rapid mobilization of cells and an excellent safety profile. These findings were presented at the 67th ASH Annual Meeting.
Read more →XCURExicure, Inc. Reports Third Quarter 2025 Financial Results
Exicure, Inc. reported its financial results for Q3 2025, showing a net loss of $2.4 million, up from $1.1 million in Q3 2024. The company’s cash position has declined to $4.4 million, raising concerns about its ability to fund operations. Increased expenses were attributed to the acquisition of GPCR Therapeutics USA Inc., and management indicated a need for substantial additional financing.
Read more →XCURNew Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Exicure, Inc. announced that results from its Phase 2 study of burixafor will be presented at the 67th ASH Annual Meeting. The study demonstrated an excellent safety profile and effective mobilization of hematopoietic progenitor cells in multiple myeloma patients. The oral presentation will take place on December 8, 2025, highlighting promising data.
Read more →XCURExicure Highlights Recent Achievements and Near-term Strategic Priorities
Exicure, Inc. has reported significant progress on its lead program, burixafor (GPC-100), which is nearing a key Phase 2 trial readout for multiple myeloma. Interim results indicate 100% success in stem cell mobilization. The company is also preparing to expand burixafor's application to other diseases and has strengthened its leadership team with experienced professionals in drug development.
Read more →XCURExicure, Inc. Reports Second Quarter 2025 Financial Results
Exicure, Inc. reported its second quarter 2025 financial results, revealing a net loss of $2.6 million, a significant increase compared to the previous year's loss of $0.6 million. This loss was primarily attributed to higher operating expenses following the recent acquisition of GPCR Therapeutics. The company's cash reserves have declined to $7.9 million, raising concerns about its financial stability and ability to continue its operations without additional funding. Management indicated the need for substantial financing in the short term to sustain the business.
Read more →XCUR▲ +10.4%on this news
Exicure, Inc. ( Nasdaq XCUR) Regains Compliance with Nasdaq Filing Requirements Redwood City, CA (BUSINESS WIRE)
Exicure, Inc. announced that it has regained compliance with Nasdaq's filing requirements as of July 1, 2025. A notice from Nasdaq confirmed the resolution of the compliance matter following the filing of its periodic reports for the fiscal quarter ended March 31, 2025. The company, which focuses on developing nucleic acid therapies, is currently exploring strategic alternatives to maximize value for its shareholders. This compliance marks a positive turn for the company amidst its restructuring efforts.
Read more →XCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q Redwood City, CA (BUSINESS WIRE)
Exicure, Inc. has received a notice of non-compliance from Nasdaq due to the late filing of its Form 10-Q for the quarter ending March 31, 2025. The Company has 60 days to submit a plan to regain compliance, with the possibility of an extension up to 180 days if accepted by Nasdaq. Exicure is diligently working to complete the necessary filings and maintain its listing on the exchange.
Read more →XCURExicure, Inc. Reports Full Year 2024 Financial Results CHICAGO, IL
Exicure, Inc. has reported its full-year 2024 financial results, revealing a significant cash position increase to $12.5 million. However, the company suspended all research and development activities and is exploring strategic alternatives due to concerns about funding operations. Their net loss decreased to $(9.7) million, yet there remains a substantial doubt about the company's viability without additional financing. Legal expenses related to litigation have also increased, indicating ongoing challenges.
Read more →XCUR▼ -15.1%on this news
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics, Inc. CHICAGO, IL.
Exicure, Inc. has entered a Share Purchase Agreement with GPCR Therapeutics, Inc., acquiring GPCR USA to enhance its technology portfolio. In tandem with this acquisition, they established a License and Collaboration Agreement to develop GPCR's therapeutics and address milestone payments related to clinical trials and royalties. GPCR USA is advancing a Phase 2 clinical trial focused on blood cancer treatments. However, Exicure is currently navigating potential Nasdaq listing compliance issues which could impact its operations going forward.
Read more →XCUR▲ +18.6%on this news
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes CHICAGO, IL.
Exicure, Inc. announced the approval of an $8.7 million equity financing from HiTron Systems Inc. by shareholders during a Special Meeting held on December 17, 2024. Following this investment, HiTron will become the company's largest shareholder, owning over 50%. The funds from this financing are expected to assist Exicure in meeting regulatory compliance requirements for Nasdaq listing. Additionally, the company is undergoing changes in executive management and board composition to support its strategic focus on developing its core pipeline.
Read more →XCUREXICURE, INC. UNAUDITED PROFORMA CONSOLIDATED BALANCE SHEETS (in thousands)
Exicure, Inc. has published its unaudited proforma consolidated balance sheets for October 31, 2024, and December 17, 2024. The financial data reveals a notable increase in total assets from $10,163,000 to $12,912,000, primarily driven by an increase in cash and cash equivalents. However, the company's accumulated deficit has worsened slightly, indicating ongoing financial challenges. Total liabilities have decreased marginally, reflecting a positive trend in financial management.
Read more →XCUR▲ +16.5%on this news· ran to +113% by day 3
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results CHICAGO, IL
Exicure, Inc. announced purchase agreements for equity financing totaling $10 million, which includes an initial sale of $1.3 million and a subsequent agreement for $8.7 million, pending stockholder approval. The company has been struggling to meet Nasdaq listing requirements but believes the initial sale will help in achieving compliance. Despite experiencing a reduction in net losses compared to the previous year, Exicure’s cash reserves are dangerously low, necessitating further funding in the near future. The company's ongoing exploration of strategic alternatives follows a recent significant restructuring and halting of R&D activities.
Read more →XCURExicure, Inc. Receives Extension from Nasdaq Hearings Panel CHICAGO, IL.
Exicure, Inc. has received a listing extension from the Nasdaq Hearings Panel, allowing until November 14, 2024, to meet compliance criteria. The company has recently regained compliance with the minimum bid price requirement and exchanged $1,000,000 of debt for equity. However, concerns remain regarding its ability to address existing and potential deficiencies, raising the risk of delisting. Exicure is exploring strategic alternatives to maximize shareholder value following its restructuring.
Read more →XCUR▼ -9.5%on this news· ran to -25% by day 1
Exicure, Inc. Announces 1-for-5 Reverse Stock Split CHICAGO, IL.
Exicure, Inc. has announced a 1-for-5 reverse stock split to comply with Nasdaq listing rules. Effective August 27, 2024, the number of outstanding shares will decrease from approximately 8.65 million to about 1.73 million. Stockholders approved the split at a recent special meeting, and it will not affect the number of authorized shares. The company is also navigating challenges as it seeks to enhance shareholder value amid its ongoing restructuring efforts.
Read more →XCUR▲ +9.8%on this news
Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting CHICAGO, IL
Exicure, Inc. announced the additional adjournment of its Special Meeting of Stockholders, initially set for August 15, 2024, and reconvened on August 19, 2024. The meeting was adjourned again as the company failed to achieve a quorum, with only approximately 49.7% of outstanding shares represented. A new reconvening has been scheduled for August 20, 2024. The company is encouraging stockholders to vote via online platforms to ensure their input is counted during this crucial meeting.
Read more →XCURExicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting CHICAGO, IL
Exicure, Inc. has announced the adjournment of its Special Meeting of Stockholders due to insufficient quorum, with only 49.4% of outstanding shares represented. The meeting will be reconvened on August 19, 2024, to solicit further votes on proposals outlined in the company's proxy statement. Stockholders who have already voted do not need to act again, while those yet to vote are encouraged to do so promptly. The company remains focused on exploring strategic alternatives after recently restructuring and halting clinical activities.
Read more →XCUR▲ +13%on this news· ran to +51% by day 1
Exicure, Inc. Receives Positive Listing Determination from Nasdaq CHICAGO, IL.
Exicure, Inc. has received a positive determination from the Nasdaq Hearings Panel to continue its listing on The Nasdaq Capital Market, provided it meets compliance criteria by September 16, 2024. The company is working diligently to satisfy these terms following its recent restructuring and suspension of clinical activities. Exicure is also exploring strategic alternatives to enhance stockholder value amidst these challenges. However, they face uncertainties regarding compliance with Nasdaq's listing requirements and potential delisting.
Read more →XCURExicure, Inc. Reports First Quarter 2024 Financial Results CHICAGO, IL
Exicure, Inc. reported its first-quarter financial results for 2024, revealing a significant decrease in cash reserves and a net loss of $0.8 million. The company is currently facing challenges with funding, having recently halted R&D activities and significantly reduced expenses. Additionally, Exicure entered a licensing agreement that may provide some financial relief, but it has acknowledged the urgent need for further capital to sustain its operations. The company is exploring strategic alternatives amid these financial difficulties.
Read more →XCUR▼ -5.3%on this news· ran to -30% by day 3
Exicure, Inc. Reports Full Year 2023 Financial Results CHICAGO, IL
Exicure, Inc. reported its financial results for 2023, showing a significant deterioration in its cash position and a substantial net loss. The company's cash and cash equivalents plummeted from $8.6 million to $0.8 million, raising concerns about its ability to fund operations. The reduction in research and development expenses reflects the halt of all clinical and preclinical activities as part of a broader restructuring effort. Exicure is currently in need of additional financing to continue operations and is exploring strategic alternatives.
Read more →XCURExicure, Inc. Received Nasdaq Notice of a Delisting Determination CHICAGO, IL.
Exicure, Inc. has received a notice of delisting from Nasdaq due to its failure to file the mandatory Form 10-K for 2023 and certain quarterly reports. The company is at risk of having its common stock suspended from trading starting May 30, 2024, unless it successfully appeals the determination by May 28. To address the situation, Exicure plans to appeal and submit a compliance plan, while its management is working to finalize the outstanding filings. The company is also exploring strategic alternatives following a restructuring.
Read more →XCURExicure, Inc. Reports Third Quarter 2023 Financial Results CHICAGO, IL
Exicure, Inc. reported its third quarter financial results, revealing a steep decline in cash reserves from $8.6 million at the end of 2022 to just $0.9 million by September 30, 2023. The company has suspended all research and development activities, resulting in zero R&D expenses for this quarter, which reflects a drastic reduction in operational activities. Additionally, Exicure reported a net loss of $5.3 million, slightly up from $5.2 million in the same quarter last year, underlining financial instability. The management indicated that extensive additional funding is required imminently to continue operations and explore strategic alternatives.
Read more →XCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K CHICAGO, IL.
Exicure, Inc. received a delinquency notice from Nasdaq for failing to timely file its Form 10-K for the year ended December 31, 2023. This marks an ongoing issue, as the company previously struggled to submit its Form 10-Q for the quarter ending September 30, 2023. Exicure must submit an update plan to regain compliance by May 20, 2024, and is actively working to file its overdue reports as soon as possible amidst exploring strategic alternatives.
Read more →XCURExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis CHICAGO, IL.
Exicure, Inc. and Bluejay Therapeutics Inc. have announced a patent license agreement focused on the development of cavrotolimod for hepatitis treatment. Under this agreement, Bluejay obtains an exclusive license for all relevant patents from Exicure. While Exicure has historically concentrated on oncology, this partnership allows for the expansion of cavrotolimod's applications. Exicure will also receive royalties from potential future sales, despite facing challenges from prior restructuring efforts.
Read more →XCURExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q CHICAGO, IL.
Exicure, Inc. received a delinquency notice from Nasdaq due to its late filing of Form 10-Q for the quarterly period ending September 30, 2023. The company has been given 60 days to submit a compliance plan and may have up to 180 days to rectify the situation if the plan is approved. Despite the challenges of non-compliance and recent restructuring, Exicure is actively seeking strategic alternatives to enhance stockholder value.
Read more →XCURExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors CHICAGO, IL.
Exicure, Inc. has announced the appointment of Paul Kang as the new CEO and Jiyoung Hwang as the new CFO, effective August 21, 2023. These changes follow the resignations of previous executives, including CEO Jung-Sang Kim. The company aims to align its management and board toward a common strategic vision and maximize value for stockholders. Exicure is also looking into strategic alternatives following a suspension of its clinical activities.
Read more →XCURExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update CHICAGO, IL.
Exicure, Inc. has reported its financial results for the second quarter of 2023, highlighting a continued suspension of research and development activities. As of June 30, 2023, the company's cash position has decreased significantly compared to the previous year. Exicure is seeking strategic alternatives to maximize stockholder value and anticipates needing substantial additional financing to support its operations moving forward. The company has entered into agreements to purchase convertible bonds as part of its investment strategy amidst ongoing challenges.
Read more →XCUR▲ +7.9%on this news
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update CHICAGO, IL.
Exicure, Inc. reported its financial results for the first quarter of 2023, highlighting a cash increase to $11.2 million and a notable decrease in research and development expenses due to a prior restructuring. The company faced a net loss of $4.4 million, an improvement from the previous year's loss. Despite these cost reductions, Exicure has suspended its R&D activities and is exploring strategic alternatives to maximize shareholder value. The management emphasizes that substantial additional financing will be necessary in the coming months, but it remains uncertain if this can be achieved on acceptable terms.
Read more →XCURExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives 5 26 2023 CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq XCUR), ("Exicure" or the "Company"), historically an early-stage biote
Exicure, Inc. has received full support from its Board for CEO Jung Sang Kim's strategic vision as the company explores various strategic alternatives aimed at maximizing stockholder value. This initiative may include potential asset sales and partnerships with industries outside its traditional operations. Although the company aims to move forward expeditiously, there is no guarantee that these efforts will culminate in successful transactions. Additionally, following recent restructuring, Exicure has suspended its clinical and development activities.
Read more →XCURExicure, Inc. Announces Investment in Korean SNS Platform Cyworld CHICAGO, IL.
Exicure, Inc. has announced a $1 million investment in Korean SNS platform Cyworld Z Co. Ltd., marking a strategic shift for the company. Historically focused on nucleic acid therapies, Exicure aims to explore new avenues to maximize stockholder value after recent restructuring efforts. Cyworld has gained popularity as the top downloaded app in Korea, boasting 32 million members and significant backing from major IT and K-culture companies. This investment may signal Exicure's intention to diversify beyond its traditional biotech focus.
Read more →XCUR▼ -5.3%on this news· ran to -16% by day 1
Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update CHICAGO, IL.
Exicure, Inc. reported its financial results for 2022, highlighting a significant net loss of $2.6 million, a reduction from the previous year's loss. Following a restructuring, the company has suspended clinical and development activities while exploring strategic alternatives and partnerships. Additionally, Exicure is facing challenges in funding its operations, anticipating a necessary substantial additional financing. While the company reported an increase in revenues due to accounting adjustments related to previous collaborations, it currently has no ongoing revenue sources.
Read more →XCURExicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements - Exicure and AbbVie have terminated their agreement relating to the development programs targeting hair loss disorders - Exicure and Ipsen
Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements -Exicure and AbbVie have terminated their agreement relating to the development programs targeting hair loss disorders -Exicure and Ipsen have terminated their agreement relating to the development
Read more →XCURExicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update CHICAGO, IL.
Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update CHICAGO, IL. - November 14, 2022 - Exicure, Inc. (Nasdaq XCUR), an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting ribonucleic acid aga
Read more →XCUR▲ +10.4%on this news
Exicure, Inc. Enters into Definitive Agreement with CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives - Upon satis
Exicure, Inc. Enters into Definitive Agreement with CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives -Upon satisfaction of certain closing conditions including approval by
Read more →XCURExicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress Company advancing SCN9A preclinical discovery program CHICAGO, IL.
Exicure, Inc. Reports Second Quarter 2022 Financial Results and Corporate Progress Company advancing SCN9A preclinical discovery program CHICAGO, IL. - August 15, 2022 - Exicure, Inc. (Nasdaq XCUR), an early-stage biotechnology company focused on the development of next generat
Read more →XCURExicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement CHICAGO, IL.
Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement CHICAGO, IL. - July 20, 2022 - Exicure, Inc. (Nasdaq XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic
Read more →XCUR▼ -27.8%on this news· ran to -48% by day 3
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split CHICAGO, IL.
Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split CHICAGO, IL. - June 29, 2022 - Exicure, Inc. (NASDAQ XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid
Read more →XCURExicure, Inc. Announces Adjournment of Annual Meeting of Stockholders CHICAGO, IL.
Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders CHICAGO, IL. - May 27, 2022 - Exicure, Inc. (NASDAQ XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and no
Read more →XCUR▼ -6.2%on this news
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress Recently announced a $5.0 million raise in a private placement transaction led by a subsidiary of CBI Co., Ltd. ("CBI"), a member of a lea
Exicure, Inc. Reports First Quarter 2022 Financial Results and Corporate Progress Recently announced a $5.0 million raise in a private placement transaction led by a subsidiary of CBI Co., Ltd. ("CBI"), a member of a leading investment group in South Korea focusing on assisting
Read more →XCUR▲ +6.2%on this news· ran to +23% by day 3
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium Proceeds expected to support Exicure's continued advancement of preclinical candidates including its SCN9A product candidate, a
Exicure Announces $5 Million Raise in Private Placement Transaction Priced at Market Premium Proceeds expected to support Exicure's continued advancement of preclinical candidates including its SCN9A product candidate, a non-opioid pain analgesic The private placement is being
Read more →XCUR▼ -16.7%on this news· ran to -37% by day 1
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress Continues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by
Exicure, Inc. Reports Full Year 2021 Financial Results and Corporate Progress Continues to advance preclinical discovery of its SCN9A research program, anticipates reporting results from initial in vivo animal studies by year-end 2022 Continues progression of work with partnere
Read more →XCURExicure, Inc. Announces Leadership Transition and Changes to the Board of Directors Brian C. Bock to resign as President and CEO and become Special Advisor to the CEO for a transition period Dr. Matthias Schroff appointe
Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors Brian C. Bock to resign as President and CEO and become Special Advisor to the CEO for a transition period Dr. Matthias Schroff appointed President and CEO will replace Mr. Bock on Board of Dir
Read more →XCUREXICURE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Exicure, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Dec. 24, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) in the United States Distri
Read more →XCUR▼ -40.7%on this newsshared move
EXICURE ALERT: Bragar Eagel & Squire, P.C. is Investigating Exicure, Inc. on Behalf of Exicure Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) on behalf of Exicure stockholders. Our investigation c
Read more →XCUR▼ -40.7%on this newsshared move
EXICURE DEADLINE ALERT: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Exicure To Contact Him Directly To Discuss Their Options
NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Exicure, Inc. (“Exicure” or the “Company”) (NASDAQ: XCUR) and reminds investors of the February 11, 2022 deadline to seek the role o
Read more →XCUREXECUTION VERSION
STRICTLY CONFIDENTIAL Attn Brian C. Bock, Chief Financial Officer This letter agreement (this "Agreement") constitutes the agreement between Exicure, Inc. (the "Company") and H.C. Wainwright Co., LLC ("Wainwright"), that Wainwright shall serve as the exclusive underwriter, agen
Read more →XCURExicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus - Exicure will reduce its workforce by approximately 50%, along with th
Exicure, Inc. Announces Results of Internal Investigation and Implementation of Strategic Measures to Reduce Cash Burn and Prioritize Pipeline Focus -Exicure will reduce its workforce by approximately 50%, along with the implementation of other cost-cutting measures - -Company
Read more →XCUR▼ -30.1%on this news
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress Chicago, IL and Cambridge, MA
Exicure, Inc. Reports Third Quarter 2021 Financial Results and Corporate Progress Chicago, IL and Cambridge, MA - November 19, 2021 - Exicure, Inc. (NASDAQ XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology, today r
Read more →XCURExicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress Entered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders Presented Progress in Three Promising Neuroscie
Exicure, Inc. Reports Second Quarter 2021 Financial Results and Corporate Progress Entered Exclusive Collaboration with Ipsen Targeting Two Rare Neurodegenerative Disorders Presented Progress in Three Promising Neuroscience Programs including Friedreich's Ataxia, Neuropathic Pa
Read more →XCURExicure Provides Interim Results from Ongoing Phase 1b 2 Clinical Trial of Cavrotolimod (AST-008) - Response rate threshold achieved to continue advancing patient enrollment in Phase 2 Merkel cell carcinoma (MCC) dose-ex
Exicure Provides Interim Results from Ongoing Phase 1b 2 Clinical Trial of Cavrotolimod (AST-008) -Response rate threshold achieved to continue advancing patient enrollment in Phase 2 Merkel cell carcinoma (MCC) dose-expansion cohort -Confirmed overall response rate (ORR) of 21
Read more →XCURAbout Exicure, Inc. Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nuc
Exicure Announces Appointment of Brian C. Bock as Chief Financial Officer (CFO) CHICAGO, IL and CAMBRIDGE, MA - May 13, 2021 - Exicure, Inc. (NASDAQ XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology, today announce
Read more →XCURExicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress - Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs - Chicago, IL. and
Exicure, Inc. Reports First Quarter 2021 Financial Results and Corporate Progress - Company Advances Clinical and Pre-Clinical Pipeline Designed to Bring Therapies to Patients With Unmet Medical Needs - Chicago, IL. and Cambridge, MA. - May 12, 2021 - Exicure, Inc. (NASDAQ XCUR
Read more →XCURExicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress - Granted two Fast Track designations for cavrotolimod (AST-008) from the U.S. Food and Drug Administration (FDA) in January 2021 and an Orpha
Exicure, Inc. Reports Full Year 2020 Financial Results and Corporate Progress -Granted two Fast Track designations for cavrotolimod (AST-008) from the U.S. Food and Drug Administration (FDA) in January 2021 and an Orphan Drug Designation in March 2021 -Commenced IND-enabling st
Read more →XCURExicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod CHICAGO and Cambridge, Mass.
Exicure Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Cavrotolimod CHICAGO and Cambridge, Mass.-March 3, 2021-Exicure, Inc. (NASDAQ XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology,
Read more →XCURExicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration CHICAGO and Cambridge, Mass.
Exicure Granted Two Fast Track Designations for Cavrotolimod (AST-008) from the U.S. Food and Drug Administration CHICAGO and Cambridge, Mass.-January 11, 2021 - Exicure, Inc. (NASDAQ XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic aci
Read more →XCUR8k_010721
8k_010721
Read more →XCURExicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress CHICAGO and Cambridge, Mass.
Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress CHICAGO and Cambridge, Mass.-November 12, 2020 - Exicure, Inc. (NASDAQ XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology, today re
Read more →XCURExicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress CHICAGO and Cambridge, Mass.
Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress CHICAGO and Cambridge, Mass.-August 12, 2020 - Exicure, Inc. (NASDAQ XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology, today rep
Read more →XCURExicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008) CHICAGO & CAMBRIDGE, Mass .
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008) CHICAGO & CAMBRIDGE, Mass.-June 16, 2020-(BUSINESS WIRE)-Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic ac
Read more →XCURExicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress CHICAGO and Cambridge, Mass.
Exicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress CHICAGO and Cambridge, Mass.-May 14, 2020-- Exicure, Inc. (NASDAQ: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology, today report
Read more →XCURExicure Provides Business Update Amid COVID-19 Pandemic - Phase 2 stage of its Phase 1b/2 clinical trial of AST-008 is still expected to begin in 2nd quarter - Research labs open for critical R&D activity; progress conti
Exicure Provides Business Update Amid COVID-19 Pandemic - Phase 2 stage of its Phase 1b/2 clinical trial of AST-008 is still expected to begin in 2nd quarter - Research labs open for critical R&D activity; progress continues on Friedreich's Ataxia development and collaboration
Read more →XCURExicure, Inc. Reports Full Year 2019 Financial Results and Corporate Progress - Friedreich's ataxia chosen as first neurological indication - Reported Phase 1b data for lead immuno-oncology candidate in solid tumors - De
Exicure, Inc. Reports Full Year 2019 Financial Results and Corporate Progress - Friedreich's ataxia chosen as first neurological indication - Reported Phase 1b data for lead immuno-oncology candidate in solid tumors - Development partnership with Allergan in hair loss disorder
Read more →XCURExicure Announces Proposed Public Offering of Common Stock Published
Exicure Announces Proposed Public Offering of Common Stock Published: December 18, 2019 CHICAGO & CAMBRIDGE, MASS.-- (BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) constructs, annou
Read more →XCURExicure Reports Third Quarter 2019 Financial Results and Recent Developments CHICAGO &
Exicure Reports Third Quarter 2019 Financial Results and Recent Developments CHICAGO & CAMBRIDGE, Mass. - November 7, 2019 - Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) technology, today reported
Read more →XCURExicure Reports Second Quarter 2019 Financial Results and Recent Developments CHICAGO &
Exicure Reports Second Quarter 2019 Financial Results and Recent Developments CHICAGO & CAMBRIDGE, Mass. - August 8, 2019 - Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) constructs, today reported f
Read more →XCURExicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors CHICAGO &
Exicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors CHICAGO & CAMBRIDGE, Mass. - August 7, 2019 - Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical
Read more →XCURtrial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA. www.exicuretx.com Forward Looking Statements This press release contains forward-looking statements (including w
Exicure Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market Published: July 30, 2019 CHICAGO, Ill. & CAMBRIDGE, MASS.--(BUSINESS WIRE)--Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherica
Read more →XCURExicure Appoints Jeffrey L. Cleland and Tim Walbert to Board of Directors CHICAGO, Ill. & CAMBRIDGE, Mass.
Exicure Appoints Jeffrey L. Cleland and Tim Walbert to Board of Directors CHICAGO, Ill. & CAMBRIDGE, Mass.,- July 22, 2019 - Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) constructs, today announced
Read more →XCURExicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System Conference call scheduled for 8:00 am ET on
Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System Conference call scheduled for 8:00 am ET on June 27, 2019 CHICAGO, Ill. and CAMBRIDGE, Mass. - June 26, 2019 - Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and
Read more →XCURExicure, Inc. Reports First Quarter 2019 Financial Results and Reviews Corporate Progress CHICAGO, IL. and CAMBRIDGE, MA.
Exicure, Inc. Reports First Quarter 2019 Financial Results and Reviews Corporate Progress CHICAGO, IL. and CAMBRIDGE, MA. - May 8, 2019 - Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA ) constructs, to
Read more →XCURExicure, Inc. Reports Full Year 2018 Financial Results and Corporate Progress Completed Phase 1 clinical trials of two drugs and began public trading
Exicure, Inc. Reports Full Year 2018 Financial Results and Corporate Progress Completed Phase 1 clinical trials of two drugs and began public trading SKOKIE, Ill - March 8, 2019 - Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nuclei
Read more →XCURExicure, Inc. Provides Update on Corporate Progress and Third Quarter 2018 Financial Results
Exicure, Inc. Provides Update on Corporate Progress and Third Quarter 2018 Financial Results SKOKIE, Ill. - November 6, 2018 - Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA ) constr
Read more →XCURalso contains projections and other information concerning our industry, our business and the markets for certain therapeutics, including data regarding the estimated size of those markets, their projected growth rates a
Unless otherwise stated or the context otherwise indicates, references to "Exicure," the "Company," "we," "our," "us," or similar terms refer to Exicure, Inc. and our wholly-owned subsidiary, Exicure Operating Company. DESCRIPTION OF OUR BUSINESS We are a clinical-stage biotech
Read more →XCURExicure, Inc. Provides Update on Corporate Progress and Second Quarter 2018 Financial Results
Exicure, Inc. Provides Update on Corporate Progress and Second Quarter 2018 Financial Results SKOKIE, Ill. - August 6, 2018 - Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA ) constru
Read more →XCURExicure, Inc. Reports First Quarter 2018 Financial Results and Reviews Corporate Progress Reports progress in immuno-oncology and neurology programs SKOKIE, IL.
Exicure, Inc. Reports First Quarter 2018 Financial Results and Reviews Corporate Progress Reports progress in immuno-oncology and neurology programs SKOKIE, IL. - May 15, 2018 - Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensiona
Read more →XCURExicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis Chicago, Illinois - April 30th, 2018 - Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA ) con
Read more →XCURExicure, Inc.
Exicure, Inc. Reports Full Year 2017 Financial Results and Corporate Progress Launched Phase 1 clinical trial of AST-008, a TLR9 agonist for immuno-oncology SKOKIE, IL - March 09, 2018 - Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-d
Read more →XCUREXICURE, INC. (formerly AuraSense Therapeutics, LLC) INDEX TO FINANCIAL STATEMENTS PAGE Audited Financial Statements
AuraSense Therapeutics, LLC) INDEX TO FINANCIAL STATEMENTS PAGE Audited Financial Statements December 31, 2016 Independent Auditors Report 2 Balance Sheets as of December 31, 2016 and 2015 3 Statements of Operations for the years ended December 31, 2016 and 2015
Read more →XCURExicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
SKOKIE, Ill., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced results from the Phase 1 clinical trial of its compound, AST-005, a SNA designed to reduce th
Read more →XCURExicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
SKOKIE, Ill., April 26, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced the dosing of the first patient in a Phase 1 trial of its AST-005 gel for chronic plaque pso
Read more →XCURExicure Co-Founder Awarded Prestigious Dan David Prize
SKOKIE, Ill., Feb. 12, 2016 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the recipient of the 2016 Dan David Prize in the Future Time Dimension. Dr. Mirkin is being awarded the prize for his grou
Read more →XCURExicure Co-Founder Awarded Inaugural Sackler Prize
SKOKIE, Ill., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the inaugural recipient of the Raymond and Beverly Sackler Prize in Convergence Research from the National Academy of Scie
Read more →Competitive Position
How XCUR ranks across every disease it competes inCompetitive Position is a premium feature
See how XCUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial